Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sana Biotechnology (NASDAQ: SANA) has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Steve Harr, will deliver a presentation featuring a business overview and update on Wednesday, January 15, 2025, at 9:00 a.m. PT.
The presentation will be accessible via webcast on the Investor Relations section of Sana's website. Interested parties who cannot attend live can access a replay of the presentation, which will remain available on the company's website for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA) ha annunciato la sua prossima partecipazione al 43° Annuale J.P. Morgan Healthcare Conference. Il Presidente e CEO dell'azienda, Steve Harr, terrà una presentazione che includerà una panoramica dell'azienda e aggiornamenti mercoledì 15 gennaio 2025, alle 9:00 AM PT.
La presentazione sarà accessibile tramite webcast nella sezione Relazioni con gli Investitori del sito web di Sana. Le parti interessate che non possono partecipare dal vivo possono accedere a una registrazione della presentazione, che sarà disponibile sul sito dell'azienda per 30 giorni dopo la conferenza.
Sana Biotechnology (NASDAQ: SANA) ha anunciado su próxima participación en la 43ª Conferencia Anual de Salud J.P. Morgan. El presidente y CEO de la compañía, Steve Harr, ofrecerá una presentación que incluirá una visión general del negocio y actualizaciones el miércoles 15 de enero de 2025, a las 9:00 AM PT.
La presentación estará disponible a través de una transmisión en vivo en la sección de Relaciones con Inversionistas del sitio web de Sana. Las partes interesadas que no puedan asistir en vivo podrán acceder a una repetición de la presentación, que estará disponible en el sitio web de la empresa durante 30 días después de la conferencia.
사나 바이오테크놀로지 (NASDAQ: SANA)는 제43회 연례 JP 모건 헬스케어 컨퍼런스에 참여할 예정이라고 발표했습니다. 회사의 회장 겸 CEO인 스티브 하르는 2025년 1월 15일 수요일, 오전 9시(PT)에 비즈니스 개요와 업데이트를 포함한 발표를 진행할 것입니다.
발표는 사나 웹사이트의 투자자 관계 섹션을 통해 웹캐스트로 접근할 수 있습니다. 라이브 참석이 불가능한 이해관계자는 컨퍼런스 종료 후 30일 동안 회사 웹사이트에서 발표의 재방송에 접근할 수 있습니다.
Sana Biotechnology (NASDAQ: SANA) a annoncé sa prochaine participation à la 43e Conférence Annuelle J.P. Morgan Healthcare. Le président et PDG de l'entreprise, Steve Harr, présentera une conférence incluant un aperçu de l'entreprise et des mises à jour le mercredi 15 janvier 2025, à 9h00 PT.
La présentation sera accessible via un webcast dans la section Relations Investisseurs du site Web de Sana. Les parties intéressées qui ne peuvent pas assister en direct pourront accéder à un replay de la présentation, qui sera disponible sur le site de l'entreprise pendant 30 jours après la conférence.
Sana Biotechnology (NASDAQ: SANA) hat ihre bevorstehende Teilnahme an der 43. jährlichen J.P. Morgan Healthcare Conference angekündigt. Der Präsident und CEO des Unternehmens, Steve Harr, wird am Mittwoch, den 15. Januar 2025, um 9:00 Uhr PT eine Präsentation mit einer Unternehmensübersicht und aktuellen Informationen halten.
Die Präsentation wird über einen Webcast im Bereich Investor Relations auf der Website von Sana zugänglich sein. Interessierte, die nicht live teilnehmen können, haben die Möglichkeit, eine Wiederholung der Präsentation anzusehen, die für 30 Tage nach der Konferenz auf der Website des Unternehmens verfügbar bleibt.
- None.
- None.
SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PT on Wednesday, January 15, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.
The webcast will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of the presentation will be available at the same location for 30 days following the conference.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, South San Francisco, CA, and Bothell, WA. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at the 43rd Annual J.P. Morgan Healthcare Conference; and the subject matter of the Company’s presentation at the conference. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-Q dated November 8, 2024. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
When is Sana Biotechnology (SANA) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch Sana Biotechnology's J.P. Morgan Healthcare Conference presentation?
How long will Sana Biotechnology's 2025 J.P. Morgan presentation replay be available?
What topics will be covered in Sana Biotechnology's J.P. Morgan Healthcare Conference presentation?
